Pharosyn Secures €2.5 Million Funding for Revolutionary Pharma Competitive Intelligence Tool

Pharosyn, a London-based company specializing in AI infrastructure for commercial decision-making in the pharmaceutical industry, has successfully secured €2.5 million in funding to enhance its platform and facilitate broader adoption among pharmaceutical commercial and portfolio strategy teams.

Led by Moonfire, the investment round also saw participation from Entrepreneurs First, Transpose Platform, and General Advance. Co-founder Joshua Hampson expressed his pride in the current product while acknowledging the vast room for improvement, highlighting the rapid evolution of technology in the industry.

Amid a significant 2026 investment trend in AI and data infrastructure for pharmaceutical and biotech sectors, Pharosyn’s funding round aligns with this ongoing momentum. Notable investments in similar domains this year include London-based Sable Bio and Helical, showcasing the growing interest in AI-powered solutions for drug-safety intelligence and pharma R&D.

Mattias Ljungman, founder of Moonfire, commended Pharosyn’s founders for their technical expertise, determination, and global ambitions. The company, established in 2025, offers an AI-powered competitive intelligence platform tailored for biopharma organizations, leveraging data from clinical, regulatory, and commercial sources to deliver strategic insights.

Founded by Stephen Cowley and Joshua Hampson, Pharosyn combines AI research and biochemistry backgrounds from Cambridge University with extensive experience in deploying AI for financial forecasting and enterprise productivity. The platform aims to enhance commercial decision-making within pharmaceutical companies by providing deep insights, comprehensive analysis, and increased operational efficiency.

Pharosyn’s infrastructure can be integrated across various functions such as commercial strategy, portfolio strategy, business development, market research, forecasting, and competitive intelligence. Top pharmaceutical companies reportedly utilize Pharosyn to inform their strategic decisions, underscoring the platform’s value in optimizing resource allocation and decision-making processes.

In conclusion, Pharosyn’s innovative approach to AI infrastructure in the pharmaceutical industry underscores the importance of customized solutions for maintaining a competitive edge. By embedding advanced technology within pharma teams, Pharosyn aims to revolutionize commercial decision-making and drive strategic growth within the sector.